An HIV vaccine regimen tested in an early-phase clinical trial elicited robust immune responses that appeared to be stronger than those observed in a landmark 2009 study showing that a vaccine can protect people from HIV infection. These findings from the ongoing Phase I/II HVTN 100 study were published on June 10 in Lancet HIV.
The trial studied a vaccine regimen designed to improve upon the one used in the 2009 study, the U.S. Military HIV Research Program-led RV144 trial in Thailand, the only study to-date to show protection, albeit modest, in humans.
To read more click here
